Taltz
Named-patient access overview. Taltz is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Taltz (ixekizumab) is a subcutaneous injectable IL-17A inhibitor developed approximately by Eli Lilly, with US FDA approval in March 2016 for moderate-to-severe plaque psoriasis in adults, subsequent expansion to psoriatic arthritis in 2017, ankylosing spondylitis in 2019, non-radiographic axial spondyloarthritis in 2020, and a pediatric psoriasis expansion in 2020 for patients 6 years and older.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Taltz
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Taltz is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Taltz in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Taltz
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.